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Abstracts A113
SIONS: Medical treatment costs in the year after initiation on duloxetine decreased 
by a greater amount among duloxetine patients with greater persistence compared to 
those who discontinued early. The ﬁndings underscore the importance of sufﬁcient 
length of therapy for major depressive disorder.
PMH47
THE ECONOMIC IMPACT OF ARIPIPRAZOLE AMONG PERSONS WITH 
SCHIZOPHRENIA IN MEXICO
Uc-Coyoc R1, Juarez-Garcia A1, Martel-Gamez V1, Rangel S1, Donato BM2
1Bristol Myers Squibb, D.F., Mexico, 2Bristol-Myers Squibb Co, Wallingford, CT, USA
OBJECTIVES: The overall cost of care for patients with schizophrenia can increase 
considerably, due to management of diseases related to the metabolic syndrome such 
as coronary heart disease (CHD) and diabetes. In the STAR study, aripiprazole is a 
second-generation antipsychotic that has shown relatively less adverse metabolic 
effects than other antipsychotics. The objective of this study is to estimate the avoided 
cost of CHD and diabetes with the use of aripiprazole compared with the standard 
of care (SOC) treatment (olanzapine, quetiapine and risperidone) in Mexico. 
METHODS: Predictions of avoided diabetes and CHD for patients receiving aripip-
razole or SOC were based on risk factor data on metabolic outcomes from the STAR 
study and related published articles. These calculations were applied to the Mexican 
population considering a schizophrenia prevalence of 0.7%. The annual cost per 
patient for the treatment of diabetes and CHD in Mexico was obtained from the 
literature review indexed to 2009 prices using the national consumption index for 
health. Cost calculations were discounted by an annual rate of 3.5% and expressed 
in US dollars at an exchange rate of $13.53 Mexican pesos per dollar. RESULTS: The 
estimated number of avoided cases of diabetes and CHD were of 23.4 and 3.7 per 
1000 treated patients with aripiprazole compared with SOC. If patients were treated 
with aripiprazole as the ﬁrst agent, the accumulated direct avoided costs over a 10 
year period for diabetes would be of US$10 millions and for CHD would be of US$17 
million. This represents total accumulated savings for the Mexican Health Care system 
of US$27 millions during this period. CONCLUSIONS: Usage of aripiprazole in the 
Mexican Health Care system can be translated into a signiﬁcant reduction of health 
care costs due to the favorable metabolic proﬁle of this drug when compared to SOC.
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OBJECTIVES: A new cost-effectiveness model, using head-to-head data, was devel-
oped to validate results from a prior indirect analysis comparing olanzapine with 
ziprasidone in the treatment of schizophrenia from the perspective of a third-party 
payer in the United States. METHODS: A decision analytic modeling approach was 
used to estimate the annual medical costs and health outcomes associated with treat-
ment of schizophrenia with the 2 comparators. The decision-tree structure included 
branches representing key clinical events such as response, relapse, and suicide 
attempts/completion. Patients without response to ﬁrst-line treatment switched to the 
other comparator. Decision-tree probabilities were extracted from a head-to-head 
study and other published clinical literature. Direct medical costs and quality-adjusted 
life years (QALYs) were estimated based on resource use (inpatient, outpatient, 
suicide, and drug costs) and utility weights for initial and relapse episodes, mainte-
nance therapy, and extended episodes of schizophrenia. Disutilities associated with 
adverse events (extrapyramidal symptoms [EPS], we ight gain, and hypotension) were 
also considered. One-way and probabilistic sensitivity analyses were performed. 
RESULTS: First-line treatment with olanzapine was associated with fewer hospital 
days, fewer EPS days, and greater number of QALYs than ﬁrst-line treatment with 
ziprasidone. Drug costs were higher for the olanzapine pathway; however, total costs 
were lower for the olanzapine pathway than the ziprasidone pathway due to cost 
savings associated with better health outcomes and less medical resource use. The 
incremental cost per QALY gained indicated that the olanzapine pathway dominated 
the ziprasidone pathway. The one-way and probabilistic sensitivity analyses conﬁrmed 
the robustness of the model and its results. CONCLUSIONS: The model conﬁrms 
results of the previous model and indicates that olanzapine is associated with better 
expected health outcomes and lower costs than ziprasidone. Despite a potential 
increase in drug costs, treating schizophrenia with olanzapine instead of ziprasidone 
could lead to cost savings for payers in the United States.
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OBJECTIVES: Recent approval by the US Food and Drug Administration of three 
atypical antipsychotics–aripiprazole, quetiapine, and olanzapine–as adjunctive therapy 
in adult patients with MDD makes examination of their cost-effectiveness important 
from a payer perspective. METHODS: We developed a decision-analytic model 
to estimate expected outcomes and economic costs in adults with MDD receiving 
aripiprazole (2–20 mg/day), quetiapine (150 mg/day or 300 mg/day), or olanzapine 
(6–18 mg/day as a ﬁxed-dose combination with ﬂuoxetine [50 mg]) as adjunctive 
therapy to ADT. Cost-effectiveness was assessed in terms of the ratio of the expected 
difference in costs of MDD-related care to the expected difference in clinical response 
(≥50% reduction from baseline in Montgomery-Asberg Depression Rating Scale) at 6 
weeks (i.e., cost per additional responder). Expected costs of MDD-related care 
included study medication, and monitoring and treatment of adverse events. Model 
parameters were estimated using data from Phase III trials and published literature. 
RESULTS: With ADT alone, the expected rate of clinical response at 6 weeks was 
estimated to be 30%. Adjunctive therapy with aripiprazole, quetiapine 150 mg/day, 
quetiapine 300 mg/day, and olanzapine was estimated to increase clinical response at 
6 weeks to 49%, 34%, 38%, and 45%, respectively. Costs of MDD-related care over 
6 weeks were estimated to be $164 for ADT alone, $714 for aripiprazole, $498 for 
quetiapine 150 mg/day, $606 for quetiapine 300 mg/day, and $669 for olanzapine. 
Cost per additional responder (vs ADT) was estimated to be $2798 for aripiprazole, 
$7996 for quetiapine 150 mg/day, $5706 for quetiapine 300 mg/day, and $3324 for 
olanzapine. The cost-effectiveness of adjunctive therapy was most sensitive to the 
estimated rate of clinical response at 6 weeks and the cost of adjunctive therapy. 
CONCLUSIONS: Adjunctive therapy with atypical antipsychotics substantially 
increases clinical response at 6 weeks. Cost per additional responder is lower for 
aripiprazole than quetiapine or olanzapine.
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OBJECTIVES: Schizophrenia is a severe chronic psychiatric disease with high treat-
ment costs and social burden. Iloperidone is a recently FDA approved atypical anti-
psychotic medication for the acute treatment of adult patients with schizophrenia. The 
aim of this study is to compare the efﬁcacy and cost of oral iloperidone with olanzap-
ine and haloperidol in a cohort with acute schizophrenia over a 1 year period. 
METHODS: Published literature and clinical expert opinions were used to populate 
a Markov simulation model using TreeAge Pro 2009 software. The model consists of 
nine 6-week cycles. Clinical response is deﬁned as ≥20% reduction in Positive and 
Negative Syndrome Scale total scores (PANSS-T) from baseline. Responders can exist 
in any of the following health states at the end of any cycle: Response with no adverse 
events (AEs), Response with mild-to-moderate AEs, Response with severe AEs, 
Relapse, Dropout and Suicide. Relapse is deﬁned as an increase in PANSS-T scores 
≥25% following a response period of more than 3 cycles. Efﬁcacy was determined as 
the average time spent in the Response with no AEs or Response with mild-to-mod-
erate AEs states. Direct costs included hospitalization, side effects, drugs and outpa-
tient care costs. RESULTS: The mean time patients spent as responders with no AEs 
or responders with mild-to-moderate AEs was estimated to be 5.76 cycles (241.9 days) 
with iloperidone compared to 5.96 cycles (250.3 days) and 6.17 cycles (259.1 days) 
with haloperidol and olanzapine treatments, respectively. The mean monthly treat-
ment costs were $2521, $2424 and $2292 for iloperidone, haloperidol and olanzapine, 
respectively. CONCLUSIONS: Using a Markov simulation model, olanzapine was 
more effective than either iloperidone or haloperidol with associated lower costs. 
Patients spent on average less time as responders with iloperidone treatment compared 
to haloperidol. These results may be of use when determining the most cost-effective 
treatment strategy for acute schizophrenia.
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OBJECTIVES: To compare the cost-effectiveness of treating early responders versus 
early non-responders to an atypical antipsychotic (risperidone) and the cost-effective-
ness of treating early non-responders maintained on risperidone versus those switched 
to olanzapine. METHODS: This post-hoc analysis used data from a randomized, 
double-blind, 12-week schizophrenia study (HGMN; n = 628). Participants were 
initially assigned to risperidone therapy. Early response was deﬁned as ≥20% improve-
ment on the Positive and Negative Syndrome Scale (PANSS) total score from baseline 
to 2 weeks. Early responders continued on risperidone, whereas early non-responders 
were randomized (double-blind) to continue on risperidone or switch to olanzapine 
for 10 additional weeks. Early responders and early non-responders maintained on 
risperidone were compared on health-state utilities (beneﬁts) and total cost over the 
12-week study; early non-responders maintained on risperidone or switched to olan-
zapine were compared from randomization (10 weeks). Utilities were derived from 
the PANSS and adverse events. Treatment costs were calculated using previous 
methods. A mixed model was used to compare outcomes on utilities. RESULTS: Early 
responders to risperidone had signiﬁcantly greater total utility and lower total treat-
ment costs than early non-responders to risperidone. Compared to early non-respond-
ers who continued on risperidone, those who were switched to olanzapine had 
signiﬁcantly better total utility at endpoint and numerically lower total treatment 
costs, reﬂecting signiﬁcantly lower non-medication treatment cost and higher medica-
